A Phase 2 Study of 16 alpha-[F-18]-fluoro-17 beta-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

作者：Peterson Lanell M^*; Kurland Brenda F; Schubert Erin K; Link Jeanne M; Gadi V K; Specht Jennifer M; Eary Janet F; Porter Peggy; Shankar Lalitha K; Mankoff David A; Linden Hannah M

来源：Molecular Imaging and Biology, 2014, 16(3): 431-440.

DOI：10.1007/s11307-013-0699-7

• FES-PET
• FDG-PET
• Metastatic breast cancer
• ER expression
• Endocrine therapy
• Response

16 alpha-[F-18]-fluoro-17 beta-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit.
Women with newly diagnosed metastatic breast cancer (MBC) from an ER-positive primary tumor were imaged before starting endocrine therapy. FES uptake was evaluated qualitatively and quantitatively, and associated with response and with ER expression.
Nineteen patients underwent FES imaging. Fifteen had a biopsy of a metastasis and 15 were evaluable for response. Five patients had quantitatively low FES uptake, six had at least one site of qualitatively FES-negative disease. All patients with an ER-negative biopsy had both low uptake and at least one site of FES-negative disease. Of response-evaluable patients, 2/2 with low FES standard uptake value tumors had progressive disease within 6 months, as did 2/3 with qualitatively FES-negative tumors.
Low/absent FES uptake correlates with lack of ER expression. FES-positron emission tomography can help identify patients with endocrine resistant disease and safely measures ER in MBC.

• 出版日期2014-6